Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
The Journal of Infectious Diseases|September 25, 2014
Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfectedMarta Ruiz-Riol, Anuska Llano, Javier Ibarrondo, et al.
Journal of Translational Medicine|April 17, 2015
A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaquesBeatriz Mothe, Xintao Hu, Anuska Llano, et al.
AIDS (London, England)|October 6, 2018
Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infectionLorna Leal, Alberto C Guardo, Sara Morón-López, et al.
The Lancet. Microbe|June 10, 2024
Immune responses associated with mpox viral clearance in men with and without HIV in Spain: a multisite, observational, prospective cohort studyIgor Moraes-Cardoso, Susana Benet, Julieta Carabelli, et al.
Frontiers in Immunology|November 27, 2020
Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical StudyJorge Sanchez, Elena Gonçalves, Anuska Llano, et al.
Microorganisms|May 4, 2026
Humoral Immunogenicity of SARS-CoV-2 mRNA Primary Vaccination Among People with HIVDaniel K Nomah, Alba G Robles, Andreu Bruguera, et al.
Plos One|April 5, 2013
HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in miceViraj Kulkarni, Margherita Rosati, Antonio Valentin, et al.
Plos One|January 13, 2012
CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV controlBeatriz Mothe, Anuska Llano, Javier Ibarrondo, et al.
Eclinicalmedicine|January 21, 2020
Corrigendum to 'Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)' EClinicalMedicine 11 (2019) 65-80Beatriz Mothe, Christian Manzardo, Alvaro Sanchez-Bernabeu, et al.
Nature Communications|October 30, 2022
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8<sup>+</sup> T cell immunityMiriam Rosás-Umbert, Jesper D Gunst, Marie H Pahus, et al.
Pageof 10